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Abstract
Background: An estimated 25 million people are currently infected with onchocerciasis (a parasitic infection
caused by the filarial nematode Onchocerca volvulus and transmitted by Simulium vectors), and 99% of these are in
sub-Saharan Africa. The African Programme for Onchocerciasis Control closed in December 2015 and the World
Health Organization has established a new structure, the Expanded Special Project for the Elimination of Neglected
Tropical Diseases for the coordination of technical support for activities focused on five neglected tropical diseases
in Africa, including onchocerciasis elimination.
Aims: In this paper we argue that despite the delineation of a reasonably well-defined elimination strategy, its
implementation will present particular difficulties in practice. We aim to highlight these in an attempt to ensure
that they are well understood and that effective plans can be laid to solve them by the countries concerned and
their international partners.
Conclusions: A specific concern is the burden of disease caused by onchocerciasis-associated epilepsy in
hyperendemic zones situated in countries experiencing difficulties in strengthening their onchocerciasis control
programmes. These difficulties should be identified and programmes supported during the transition from
morbidity control to interruption of transmission and elimination.
Keywords: Onchocerciasis, Control, Elimination, Monitoring & evaluation, Community drug distributors, Epilepsy,
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Background
According to the World Health Organization (WHO), at
least 25 million people are currently infected with
onchocerciasis (a parasitic infection caused by the filarial
nematode Onchocerca volvulus), and 123 million people,
99% of them in sub-Saharan Africa, live in areas that put
them at risk of infection [1, 2]. The parasite is transmitted
by Simulium (blackfly) vectors which breed in fast-flowing
waters, from which arises the name by which the disease
is best known: River Blindness. As a consequence of
onchocerciasis, before the inception of the African
Programme for Onchocerciasis Control (APOC) in 1995,
10 million people suffered from its dermatological
manifestations, with > 400 000 of them blind and 900 000
visually impaired [3]. Studies have also reported a signifi-
cant association between onchocerciasis and excess
human mortality [4, 5], as well as between onchocerciasis
and epilepsy [6–8]. Despite this, the proportion of persons
suffering from onchocerciasis-associated epilepsy remains
to be determined.
Major efforts to control River Blindness started with the
establishment of the Onchocerciasis Control Programme
in West Africa (OCP) in 1974. Through at least 14 years
of weekly aerial spraying with larvicidal insecticides of the
simuliid vectors’ riverine breeding sites, this programme
succeeded in eliminating transmission (and hence the
parasite) in virtually all of the ‘core’ savannah areas of the
seven initial OCP countries [9, 10]. Subsequently, by
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integrating this vector control with yearly mass distribu-
tion of the (broad-spectrum) anti-parasitic drug ivermec-
tin, onchocerciasis was also eliminated as a disease of
public health importance from 10 of the final 11 West Af-
rican OCP countries by the time the programme closed in
2002 [11]. In some OCP foci, onchocerciasis was elimi-
nated by (annual or biannual) mass drug administration of
ivermectin even in the absence of vector control [12, 13].
Ivermectin (Mectizan®), a safe and efficacious anthel-
mintic with effects on the microfilarial stages (among
others) of the parasite, was registered for onchocerciasis
control in 1987, and is being donated by Merck Sharp &
Dohme, MSD (known as Merck & Co. Inc. in the USA
and Canada) for use in Africa, Latin America and
Yemen for as long as necessary to eliminate the disease
as a public health problem [14]. To take advantage of
this donation, many eye-care non-governmental organi-
zations (NGOs) working with the governments of en-
demic countries began mass ivermectin treatment in the
most heavily infected communities and particularly in
Africa [15, 16]. APOC was established in 1995 to co-
ordinate and extend these activities using Community-
Directed Treatment with Ivermectin (CDTI) as its main
strategy to increase ivermectin coverage, and it aimed to
control onchocerciasis in 20 endemic countries outside
the OCP [2, 17]. Before the start of APOC in 1995, 32
million people were infected with onchocerciasis, with >
100 million of these at risk [3]. By 2014 (1 year before
APOC’s closure), 112 million people were benefitting
from CDTI, which averted annually the loss of 2 million
Disability-Adjusted Life Years (DALYS) at a cost of only
US$27 per DALY averted, making it very cost-effective
[3]. In 2010, APOC shifted its focus from control of the
disease to its elimination [18] and, in 2012, the WHO, in
its roadmap for “Accelerating work to overcome the glo-
bal impact of neglected tropical diseases” (NTDs), set
the goals of eliminating onchocerciasis in selected Afri-
can countries by 2020 [19]. Also in 2012, APOC’s Joint
Action Forum expanded this goal to 80% of endemic
countries with onchocerciasis eliminated by 2025 [20].
The aim of this paper is to argue that despite the devel-
opment of a reasonably well-defined elimination strategy
[21], its implementation will present difficulties in prac-
tice. We aim to highlight such difficulties, to try and
ensure that they are well understood so that effective
plans can be laid to solve them by the countries concerned
and their international partners through technical support
by the Expanded Special Project for the Elimination of
Neglected Tropical Diseases (ESPEN), a newly created
structure at WHO AFRO. A specific concern is the
burden of onchocerciasis-associated disease that remains
especially in hyperendemic zones situated in countries ex-
periencing difficulties in strengthening their onchocercia-
sis control programmes. These difficulties need to be
carefully identified and the programmes strongly sup-
ported during their transition from morbidity control to
interruption of transmission and elimination.
Expanded Special Project for the Elimination of
Neglected Tropical Diseases (ESPEN)
APOC closed in December 2015 and WHO has estab-
lished a new structure, the Expanded Special Project for
the Elimination of Neglected Tropical Diseases (ESPEN)
[22] for the coordination of technical support for five
NTDs in Africa, including onchocerciasis elimination
activities. The elimination efforts include extending iver-
mectin treatment to hypoendemic (previously excluded)
and operationally challenging areas, and also implement-
ing intensive surveillance. According to recent esti-
mates, this could save US$1.5–1.6 billion over 2013–
2045 compared to the scenario in which onchocercia-
sis is controlled but not eliminated [23]. The project’s
plan includes the setting up of independent ‘national
oversight committees’ for onchocerciasis elimination
in all countries with onchocerciasis endemic foci, and
recently in many countries such committees have
been established. The committees operate under a
variety of names (e.g. National Onchocerciasis Elimin-
ation Committee or NTD Technical Advisory Com-
mittee), and are in principle independent and advisory
to the ministries of health, the decision makers which
operate the national control programmes.
When the oversight committees are set up, their first
task is to review the current epidemiological situation
throughout the country. This often involves conducting
new “elimination” prevalence surveys countrywide or in
selected areas. Simultaneously, they try to define the so-
called transmission zones in every part of the country
(which will allow mapping of the hypoendemic areas
where CDTI is to be instigated – usually twice a year)
and identify sentinel sites for epidemiological and ento-
mological surveillance. A transmission zone is a geo-
graphical area where transmission of O. volvulus occurs
by locally breeding vectors and which can be regarded as
a natural ecological and epidemiological unit for inter-
vention [18]. As soon as possible, the committees start
to assess progress towards elimination in all of the trans-
mission zones, and this assessment includes prevalence
surveys and examination of CDTI coverage. This process
should identify programmatic insufficiencies in CDTI
projects already operating in meso- and hyperendemic
areas and result in appropriate corrective action. After
the national elimination programmes have finished this
initial review period, they are expected to settle into a
new phase whereby the oversight committee considers
annual progress reports from each transmission zone
and recommends as necessary to the Ministry of Health
action to reach or accelerate elimination.
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The expert advisory committees should be able to con-
sider a country’s progress towards elimination in much
greater detail than was possible by APOC. For instance,
the Uganda Onchocerciasis Elimination Expert Advisory
Committee has already played a major role in guiding
the interruption of transmission in 15 of the 17 Ugandan
foci. However, Uganda is a small country whose commit-
tee is very inclusive, with district vector control officers
attending committee meetings, presenting their reports
and participating in discussions. Furthermore, in Uganda
there has been a history of interest in onchocerciasis,
and hence there already existed significant expertise
within the Ministry of Health. Besides, Uganda has bene-
fitted from the early and effective establishment of its
advisory committee with the support of The Carter Cen-
ter [24]. Many other countries (such as Liberia) have not
had this historical head-start and may find it more diffi-
cult to make progress without significant external ex-
pertise and support. Also in large countries (Nigeria is
an example) it will not be feasible to include Ministry of
Health field operatives from all the districts as observers
on the committee. ESPEN will have a role in the support
of these expert committees which is mostly technical
but in some cases also financial. However, ESPEN
remains a small organisation and will not have the cap-
acity to intervene directly in every endemic country.
Although the replacement of APOC by ESPEN has the
potential advantage of generating a pan-African platform
for integrated NTD control, the delays in organising
ESPEN have also created some confusion and a tempor-
ary lack of direction. ESPEN has been mandated to
cover five NTDs (onchocerciasis, lymphatic filariasis,
schistosomiasis, soil-transmitted helminthiases and
trachoma) with a budget that is far from generous.
While it establishes itself, ESPEN has prioritised 14
countries for attention (Benin, Chad, Central African Re-
public, Comoros, Republic of Congo, Democratic Re-
public of the Congo, Ethiopia, Guinea, Guinea Bissau,
Nigeria, São Tomé & Príncipe, South Sudan, Tanzania
and Togo). However, these countries have been chosen
from a consideration of all five NTDs, so several of the
countries would not have been prioritised on the basis
of onchocerciasis alone, and others which have signifi-
cant onchocerciasis problems have not been included
(such as Cameroon and Sierra Leone). This may restrict
the budget available for effective onchocerciasis elimin-
ation efforts across the whole of Africa. A number of
countries (such as the UK and the USA) have stepped in
to try and fill the gaps by channelling direct country
support through various organisations including NGOs
(e.g., Sightsavers in the UK), but it is unclear whether
this commitment will be sufficient and sustained until
elimination. Whilst ESPEN’s onchocerciasis elimination
plans include the expansion of CDTI to hypoendemic
zones, there is a risk that the countries with already
weak onchocerciasis control programmes may not
receive the financial and technical support needed to im-
plement and monitor onchocerciasis elimination pro-
grammes effectively.
Eliminating onchocerciasis – The progress so far
The shift from control to elimination requires a major
change in thinking, planning, funding and national
support. In the absence of complementary vector con-
trol strategies [21], achieving good geographic and
therapeutic ivermectin coverage as well as minimising
systematic non-compliance are essential for onchocer-
ciasis elimination. The former refers to the proportion
of communities and individuals within communities
treated, and the latter to the proportion of individuals
that never take treatment. To control onchocerciasis
as a public health problem, APOC recommended a
minimum ivermectin therapeutic coverage of 65%;
however, for elimination ≥80% therapeutic coverage
and 100% geographical coverage will be needed as
already recommended [25].
Epidemiological models suggest that to achieve elimin-
ation solely by means of mass ivermectin treatment, the
minimum required therapeutic coverage of 65–80% of the
total population (aged ≥5 years) (equivalent to 80–95%
among those eligible) must be attained and sustained over
a long period whose duration depends, partly, on the base-
line level of onchocerciasis endemicity, measured by initial
microfilarial prevalence and load [26–28]. The ONCHO-
SIM and EPIONCHO models predict that the provisional
operational thresholds for treatment interruption and ini-
tiation of surveillance (pOTTIS), suggested by APOC
(2010) [18], can be reached by annual CDTI (total cover-
age 80%) within 14–17 years for mesoendemic regions,
but may require > 17 years (ONCHOSIM) or > 25 years
(EPIONCHO) for highly hyperendemic (holoendemic)
foci [28]. In both sets of simulations a 5% of systematic
non-compliers was assumed and initial prevalences
ranging from 50 to 90% were explored to cover the range
from meso- to holoendemic onchocerciasis [29]. However,
such predictions may not apply in all endemic areas in
Africa because of a) different Onchocerca–Simulium com-
plexes, particularly for forest onchocerciasis [30]; b) a
possible greater proportion of non-adherence to treat-
ment, particularly in loiasis co-endemic areas [31, 32], and
c) differences between the magnitude of the pOTTIS and
the true transmission breakpoints [28, 33]. The higher the
initial endemicity, the lower the true elimination thresh-
olds and, therefore, the less useful the current pOTTIS
are as indicative of ultimate elimination. Currently the
pOTTIS have been taken as a microfilarial prevalence <
1.4% 1 year after the last treatment round (a weighted
mean of the values proposed by APOC 2010 [18]), but
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they would have to be much more stringent in areas of
high baseline endemicity. In addition, the recent WHO
[34] elimination guidelines do not advocate the measure-
ment of microfilarial prevalence (by skin snips) among the
metrics on which to make decisions about stopping treat-
ment and verifying elimination.
APOC was set up in 1995 as a control (morbidity-reduc-
tion) programme, and following the Conference on Era-
dicability of Onchocerciasis in 2002 [35], it was
considered doubtful that elimination could be achieved in
Africa with mass administration of ivermectin alone. The
arguments put forward included the large size of oncho-
cerciasis endemic areas, the fact that these areas are often
contiguous, and that the members of the Simulium dam-
nosum s.l. complex are highly efficient in transmitting O.
volvulus. The same conclusions were reached by other au-
thors after assessing the empirical evidence available at
the time regarding the impact of repeated ivermectin mass
treatments on parasitological and transmission indices in
West Africa [36]. At the time of that publication, data on
6-monthly treatments in Africa were sparse and did not
allow conclusions to be drawn on the effectiveness of in-
creased treatment frequency. However, elimination was
thought to be possible in the Americas where onchocer-
ciasis foci were often smaller and more circumscribed,
and where some of the simuliid species involved in trans-
mission have lower vector competence [37]. Indeed, the
Onchocerciasis Elimination Program for the Americas
(OEPA) has succeeded in eliminating onchocerciasis from
Colombia, Ecuador, Guatemala, Mexico, and parts of
Venezuela [38], using mostly biannual (6-monthly, semi-
annual) treatment with ivermectin, and quarterly treat-
ments in some foci [39].
Despite the challenges in achieving good treatment
coverage in Africa, there is now a general belief that on-
chocerciasis elimination should be ultimately feasible in
most, if not all, endemic areas and there is empirical evi-
dence to support this notion. In 2005, a longitudinal
study in three initially meso- to hyperendemic onchocer-
ciasis foci (with strongly seasonal transmission by S. sir-
banum) in Mali and Senegal, where ivermectin had been
distributed for 15–17 years, documented no evidence of
transmission over a 3–5-year period after stopping treat-
ment [13]. Nevertheless, it should be noted that a recent
evaluation study which covered some of the same areas
(in the River Gambia focus of Senegal) found 7/279
children positive with antibodies for the Ov16 antigen
(the marker of exposure/infection recommended by the
recent WHO guidelines [34]). However, some of these
results could be false positives and it is not yet clear
whether this represents continuing autochthonous trans-
mission or exposure to infective larvae through the bite
of infective immigrant flies [40]. Of interest is a study
modelling elimination in the Malian and Senegalese foci
of [12, 13], which discussed the possibility of (pro-
tracted) recrudescence in the River Gambia focus based
on EPIONCHO projections [41]. Other epidemiological
studies in Kaduna State in Nigeria [42] and the Abu
Hamed focus in Sudan [43] have reported interruption
of transmission as a result of CDTI. Similarly, an inter-
national team of experts evaluated CDTI programmes
which, between 2008 and 2014, provided ivermectin for
at least 6 years; results from 12 countries showed that in
areas with adequate annual ivermectin treatment cover-
age, satisfactory progress was made towards elimination
and that 33 evaluation areas with a total population of
28 million people were close to, or had already reached,
elimination [44]. In other (East African) foci, interrup-
tion of transmission has been achieved through the dis-
appearance of the local S. neavei vector [45], or by a
combination of long-term ivermectin distribution and
vector elimination [46].
Why onchocerciasis control remains difficult in certain areas
Issues affecting coverage and access to treatment
Achieving consistently high ivermectin treatment cover-
age remains a challenge and in several African countries,
such as the Democratic Republic of the Congo (DRC),
Central African Republic (CAR), Angola, Cameroon and
South Sudan, onchocerciasis elimination may be out of
reach in the near future [23]. Onchocerciasis control has
been difficult in those African areas with initial preva-
lence greater than 60%, especially if ivermectin is only
distributed once a year. This is mainly due to the fact
that higher endemicity levels require higher coverage
and longer treatment durations. For example, by 2015,
after 15 years of CDTI, onchocerciasis was reported to
remain mesoendemic in the Centre and Littoral Regions
of Cameroon [47]. In the North and North-West of the
country, the prevalence of onchocerciasis had dramatic-
ally decreased after 17 years of CDTI but elimination
has certainly not yet been reached [48]. In the DRC not
even the target coverage for onchocerciasis morbidity
control (of 65%) had been reached by 2012 [49], let
alone the target coverage for elimination (80%).
Barriers to access to treatment and poor treatment
compliance contribute to insufficient treatment cover-
age. Although ivermectin is provided free of charge,
several onchocerciasis endemic regions still do not have
good access to treatment. For example, people may not
receive their annual treatment because of inadequate
supply as a result of underestimation of population size
[50], or because the community directed distributors
(CDDs) of ivermectin do not visit remote and inaccess-
ible areas. In Cameroon, the number of CDDs available
to cover several large villages and zones was deemed too
small [48]. In Tanzania, lack of comprehensive under-
standing of the disease, fears of medication, distrust of
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the method determining dose, lack of health education
materials, insufficient CDD-resident communication,
and inflexible drug distribution mechanisms were identi-
fied as factors affecting community participation in the
CDTI programme [51]. In South Sudan the ivermectin
distribution campaign has been disturbed by the war.
Moreover, health care providers working in remote en-
demic zones may fail to diagnose onchocerciasis due to
insufficient training and poor resources [52] and as a re-
sult, endemic zones where ivermectin needs to be dis-
tributed may be missed.
Political restructuring and inadequate assessment of
onchocerciasis endemicity can contribute to reduced
coverage. For example, in the Ituri Province in the DRC,
the lack of implementation of a CDTI programme in
certain villages was caused by the reorganization of the
health territory which resulted into the subdivision of
health zones into several health areas. The villages of
Bessi, Draju, Kanga, Ndroyi, and Wala, in the past
belonged to the health zone of Angumu (where, based
on rapid epidemiological mapping of onchocerciasis
(REMO) assessment, CDTI was needed). Later they were
integrated into the Logo health zone, a zone where
CDTI was considered not to be necessary and, therefore
the population in these villages did not receive ivermec-
tin (M. Mandro, pers. comm.).
In the majority of CDTI projects in Africa, reported
coverage has been satisfactory and, by and large, increas-
ing over time [44]. However, ivermectin coverage is
commonly calculated using the information provided by
CDDs and such estimates can easily lead to over-
estimation of coverage (particularly if population cen-
suses are not regularly updated and the CDDs treat an
increasing number of residents as populations grow but
the denominators remain the same). Furthermore, cover-
age rates in a community may give a misleading picture
of the success of control efforts; if there are individuals
or large groups who systematically do not comply with
treatment, they may provide a continued focus for trans-
mission [26, 28, 31–33, 53] and make elimination of on-
chocerciasis an unattainable goal.
Issues affecting treatment adherence
In addition to inadequate access to treatment, onchocer-
ciasis control efforts are further limited by poor compli-
ance and uptake of ivermectin in some communities,
among other factors, due to seasonal migration of
workers at the time of ivermectin distribution, lack of in-
centives for CDDs, fear of side effects and distrust of
CDDs [32]. Similar observations were made in Mahenge
in Tanzania, where it was reported (based on a household-
based survey) that during the annual 2016 CDTI round,
the majority of community members were away for farm-
ing; besides, in this locality fear of side effects was one of
the main reasons for not taking ivermectin (B. Mmbando,
unpublished data). Women in particular were more often
non-compliers because of fear of sterility [32], and since
less than 25% of CDDs are female [25], increasing this
proportion may inspire women’s confidence in taking the
treatment. In Cameroon, but something also observed in
the DRC, certain people do not take the ivermectin orally
because they use ivermectin to kill hair lice [32]. In a vil-
lage in the Bas Uele province of the DRC with a very high
prevalence of epilepsy and high exposure to Onchocerca-
infected blackflies, people had stopped taking ivermectin
because of experiencing side effects and, according to in-
formation gathered during four focus-group discussions,
having to pay for the treatment of these side effects (A.
Rotsaert, unpublished data).
Treatment compliance has been associated with being
male [50], living in an area for a longer time, and having
social support [48]. In some settings, older age is associ-
ated with ivermectin uptake [50], whilst in others youn-
ger people are more likely to have taken ivermectin [49].
Positive beliefs about ivermectin that have been associ-
ated with treatment compliance include beliefs that iver-
mectin prevents onchocerciasis and blindness [48],
induces intestinal worm expulsion, and increases vitality
[47]. Perceived personal risk of onchocerciasis [54, 55]
and positive perceptions of the programme have also
been associated with good treatment adherence, and
those that perceive CDDs as doing their work well, or
know at least one CDD in their village, are more likely
to take treatment [56].
Ivermectin treatment in loasis co-endemic areas pre-
sents one of the most important challenges [32]. Al-
though considered a “safe” drug, administration of
ivermectin to patients with both, onchocerciasis and lo-
iasis, can result in severe adverse events (SAEs), includ-
ing encephalopathy and death [57]. Early identification
and referral of cases of encephalopathy to a hospital to
provide medical and nursing care is of paramount im-
portance. Not surprisingly, a fear of SAEs is a major rea-
son for non-compliance in onchocerciasis-loiasis co-
endemic areas.
Sub-optimal responses to ivermectin
Studies in Ghana and Cameroon suggest the occurrence
of the so-called sub-optimal (or atypical) responses to
ivermectin. In these studies ivermectin still killed the
microfilariae but seemed to have become less effective in
reducing the fertility of the adult female worms [58].
This resulted in a rapid reappearance of microfilariae
and an increased risk of onchocerciasis transmission
even when the frequency of treatment had been in-
creased from annual to biannual [59]. These, essentially
phenotypic, studies have been recently complemented by
genome-wide analysis of ivermectin responses by O.
Colebunders et al. Infectious Diseases of Poverty  (2018) 7:21 Page 5 of 15
volvulus [60]. This analysis suggests that the evolution of
sub-optimal responses occurs via selective sweeps of
pre-existing quantitative trait loci rather than via selec-
tion of relatively rare resistance-conferring mutation(s).
The outcome is the accumulation of many alleles in a
limited number of functional pathways that facilitate the
recovery of adult female worm fecundity from the in-
hibitory effects of ivermectin. This is consistent with the
observation that the microfilaricidal effect of ivermectin
remains unaltered in sub-optimally responding popula-
tions, but that the difference between these and fully
ivermectin-susceptible parasites resides in quantitative
variation in the rate and extent to which microfilarial
production is resumed after treatment [60].
Cross-border issues
Cross-border onchocerciasis transmission is another
challenge for onchocerciasis control programmes that
focus only on a narrowly-defined geographical area. Par-
asites can be reintroduced into an area where CDTI has
good geographic and therapeutic coverage by immigrant
humans (including refugees or seasonal migrants) or
vectors from insufficiently controlled areas. Different
vector species differ in their propensity to disperse and
migrate. For example, S. neavei in Uganda is not known
to disperse further than a few kilometres from its breed-
ing sites, whereas S. damnosum s.str. can migrate (wind-
assisted) up to 400 km in West Africa and carry para-
sites into controlled areas [30]. Human and vector mi-
grants can carry parasites across national borders and
between foci within a country. The WHO recommends
the use of transmission zones as the units of assessment
because they are expected to be epidemiologically inde-
pendent from each other as migration between them is
deemed to be negligible [21]. The mapping of transmis-
sion zones is, therefore, important for onchocerciasis
elimination, but also problematic because patterns of
migration (of vectors and humans) will be unique to
each area and are very difficult to quantify and to map.
One possibility may be through the use of parasite gen-
etic markers to understand patterns of gene flow be-
tween populations, and recent advances in genomic
analyses of O. volvulus may facilitate this [60].
Suggestions to improve weak onchocerciasis
elimination programmes (Fig. 1)
Areas of insufficient onchocerciasis control need to be identified
Such areas are generally located in hard-to-reach areas
and populations, including in insecure areas, and there
is little information about the status of onchocerciasis
control in those settings. In South Sudan, for example,
the CDTI programme seems to have been interrupted
and there is no recent information on the onchocerciasis
situation in this country. Challenges in accessing remote
or conflict-affected areas, combined with poor resources,
mean that there is also the need for revision and devel-
opment of methodologies that will enable rapid, reliable
and cost-effective assessment of the onchocerciasis con-
trol situation. However, this is not exclusively an issue
for hard-to-reach and insecure areas. Five of the six
APOC evaluation areas that were identified by Tekle et
al. [44] as having unsatisfactory treatment coverage had
no accessibility or security problems, highlighting the
importance of monitoring and evaluation in all areas. A
high prevalence of epilepsy, and certainly a high inci-
dence of new onset epilepsy in children and youngsters
between the ages of 3 and 20 years, in an onchocerciasis
endemic area should be a reason to assess the perform-
ance of the CDTI programme. In non-onchocerciasis
endemic regions in Africa most of the seizures in persons
with epilepsy start below the age of 5 years because of ob-
stetric and perinatal problems. In highly onchocerciasis-
endemic regions, a large number of individuals may
present with seizures after the age of 5, with a peak onset
of epilepsy between the age of 8 and 12 years. The latter
type of epilepsy should be considered as an early-warning
Fig. 1 Improving weak onchocerciasis (oncho) elimination
programmes. At the core of this effort is the recognition that some
of these programmes may not reach elimination goals in the 2020/
2025 time horizons but, if strengthened, they can still achieve
substantial reductions in morbidity and mortality due to
onchocerciasis. This requires (clockwise) the identification of
under-performing programmes and investigation of the causes for
this, with particular emphasis on improving the geographic (and
therapeutic) coverage as well as treatment uptake and compliance.
Monitoring and evaluation approaches should be improved with
optimised use of current and novel tools; one such tool could be
the recognition of early stage morbidity (e.g. prevalence of epilepsy
in children) linked with serological markers of exposure
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sign of onchocerciasis-associated epilepsy (OAE) (Table 1).
Interestingly, the study by Walker et al. [5] reported that
for a given microfilarial load, the relative risk of mortality
was significantly greater in children (aged < 20 years) than
in those aged 20 years and more.
Geographical coverage of ivermectin needs to be
improved and adapted to different contexts
Ivermectin distribution strategies deployed in conflict-
affected areas may need to be different from the classical
approaches to distribution in non-conflict settings. This
could be done through collaboration with local NGOs
or international humanitarian organizations such as
International Red Cross, whose volunteers are often
present in war zones. Training additional CDDs and
providing suitable means of transportation in difficult
terrain may help to ensure that more people living in re-
mote areas have access to ivermectin.
Treatment uptake and adherence need to be improved
through sustainable community participation
An effective social marketing campaign raising awareness
about ivermectin, onchocerciasis and onchocerciasis-
associated morbidities (including OAE) may motivate
people to take up treatment and also improve adherence.
Social research on people’s attitudes and perceptions
regarding ivermectin and onchocerciasis can be used to
advise on advocacy implementation strategies and to iden-
tify contextually relevant messages to be used for advocacy
campaigns. Population groups with poor treatment uptake
and the reasons for this need to be identified. Social
science-based research can identify those strategies that,
in a given context, will help the shift from insufficient
CDTI coverage and adherence to well-performing CDTI
programmes.
Timing of CDTI rounds should be improved
Ivermectin distribution campaigns need to be well-
planned to take place at a time that ensures that the
drug is effectively deployed during the main parasite
transmission seasons (if transmission is highly seasonal),
while taking into account when people are likely to be
present in their communities and available for receiving
the treatment (e.g. not during farming/harvesting
periods). If increased treatment frequency is imple-
mented, then it is important that treatment is
administered 6-monthly to effectively curtail the trans-
mission to blackfly vectors of microfilariae reappearing
in the skin. This requires good coordination of the
distribution of the drug from central points of arrival
and storage to the districts and communities. Providing
treatment twice a year but without the necessary interim
period of 6 months between treatment rounds negates
the benefits of biannual treatment [33].
Table 1 Onchocerciasis-associated epilepsy (OAE), challenges and opportunities
New findings Challenges Opportunities
Burden of disease caused by
onchocerciasis is more important
than previously estimated
Accurate estimation of burden
of disease due to onchocerciasis,
including OAE, is a pressing need
Determination of OAE prevalence and
incidence provides an argument to strengthen
and accelerate onchocerciasis elimination
programmes by identifying areas of weakness
OAE awareness and advocacy
are inadequate
Determination of OAE prevalence and incidence
provides an argument to obtain more funding
for operational research for onchocerciasis
elimination efforts
High prevalence/ incidence
of OAE suggest ongoing
onchocerciasis transmission
Strengthen epilepsy surveillance
in onchocerciasis endemic regions
CDDs could be engaged in assisting
with epilepsy surveillance
OAE is preventable Biannual CDTI should be promoted Message will increase the motivation of
populations to take ivermectin, potentially
increasing compliance
Misconceptions and stigma
associated with epilepsy
Health promotion activities to
reduce misconceptions and
stigma among populations
OAE is treatable In onchocerciasis-endemic regions,
a decentralised system is needed
to diagnose and treat epilepsy
early and appropriately
CDDs could be trained to monitor
antiepileptic treatment adherence
Little collaboration between
onchocerciasis elimination and
mental health programmes
Onchocerciasis and public mental
health programmes working together
CDDs community drug distributors, CDTI community directed treatment with ivermectin, OAE onchocerciasis-associated epilepsy
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Representation of women among community distributors
should be increased and the motivation and training of
the CDDs should be monitored and maintained
Studies report that female CDDs may strengthen and im-
prove performance of the CDTI programme, as women
are more committed, persuasive, more patient and their
reports are more accurate [61]. Also, they may help to dis-
pel misunderstandings about treatment and infertility
among the women of the communities. However, a study
in Uganda showed that it might be difficult for female
CDDs to work effectively outside their own kinship zones
and, also, that they may face more mistrust from the com-
munity than their male counterparts [62].
The motivation of CDDs and the empowerment of
communities are essential for the success of CDTI.
Therefore, CDTI needs to be tailored to adapt to local
power structures and diverse cultural contexts. For in-
stance, in Uganda traditional social systems are very
strong in all rural communities; a kinship-enhanced
CDTI strategy that adopts collective decision-making by
community members was found to be more effective in
achieving better treatment coverage and community par-
ticipation than a classic CDTI approach, in which deci-
sions are made primarily by community leaders without
much involvement of community members [63, 64]. Im-
provement in treatment coverage observed in Uganda
was largely attributable to involvement of kinship
groups, avoidance of paying monetary incentives to the
CDDs and the satisfaction with the programme of those
who had been treated [63–65].
Maintaining commitment and motivation of CDDs is
challenging, and reduced motivation may contribute to
under-performance of CDDs. An appropriate form of
compensation for CDDs largely depends on the context
in which community leaders must agree to set their own
terms of remuneration or locally appropriate incentives
(e.g. currency, food or labour). In south-eastern Nigeria,
lack of monetary incentives led to significant increases
in CDD attrition [66], but in Plateau State the provision
of monetary incentives to CDDs resulted in several
problems, including complex logistics and making the
position so desirable that community leaders often chose
friends and relatives for the job [67]. By contrast, in
Uganda, a shift from in-kind payments towards
monetary-oriented strategies helped to achieve adequate
drug distribution in Kabarole district [68]; in contrast,
avoidance of paying monetary incentives to the ivermec-
tin distributors contributed to improved treatment
coverage in ten other districts [65].
Compensation and motivation of CDDs is very much a
local issue based on the value judgements of the CDDs.
When decisions regarding CDTI are made collectively,
by community members rather than by community
leaders and health workers on behalf of the community
members, the CDDs’ demands for monetary incentives
decline [69] but, on the other hand, CDDs who work
among non-relatives are more likely to demand
monetary incentives than those who treat relatives [63].
Treatment frequency should increase to biannual wherever
possible, particularly in highly endemic areas
Regarding treatment frequency, biannual ivermectin dis-
tribution has been shown to improve treatment uptake
[59], provide at least one treatment round in the year to
those who may have missed the previous round, and
shorten the timeframes to elimination by reducing the
transmission of microfilariae to vectors in the inter-
treatment periods [26–28], proving to be cost-effective
[33]. Therefore, weak onchocerciasis control pro-
grammes, in particular, should be supported not only to
increase their geographic and therapeutic coverage but
also to implement biannual ivermectin distribution.
Approaches to the monitoring and evaluation of
onchocerciasis control programmes should be improved
With ESPEN’s focus on onchocerciasis elimination,
there is great need for improved approaches to the
monitoring and evaluation of onchocerciasis control
efforts. In 2016, the WHO published guidelines about
how to make decisions concerning the stopping of
CDTI and the evidence required for verification of
interruption of transmission [34], but these guidelines
do not provide enough information to advise coun-
tries as to how to monitor progress towards elimin-
ation. To this end, WHO has now created a working
group to develop a programme managers’ guide.
The design of robust monitoring and evaluation ac-
tivities and the preparation of clear guidance on
these, including which data should be collected by
programmes, are the subject of ongoing statistical and
transmission dynamics modelling work. The various
strands of this work include: i) refinement of sam-
pling protocols (e.g. for parasitological, serological
and entomological assessments with current tools); ii)
incorporation as model outputs of potential additional
diagnostic tools (e.g. novel markers of female worm
reproductive activity); iii) use of statistically robust
approaches for analysis and interpretation of results;
iv) refinement of evaluation criteria and thresholds
for safe cessation of mass treatment and verification
of elimination; v) determination of optimal duration
of post-CDTI and post-elimination surveillance pe-
riods; and vi) formulation of recommended strategies
if achieving elimination proves difficult, or if infection
is reignited or reintroduced [26, 28, 41, 70, 71].
Parasitology Evaluation of progress can make use of
skin snip surveys (still the gold standard for diagnosing
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active infection), and can be conducted in parallel with
Ov16 seroprevalence surveys. However, if skin snips are
used, particularly for epidemiological evaluations con-
ducted after prolonged CDTI with good coverage, it is
recommended to test snips using PCR-based methods to
increase test sensitivity. Coverage surveys may not ne-
cessarily be the best indicators of onchocerciasis control
programmatic effectiveness for the reasons discussed
above and because of the insidious impact of systematic
non-compliance. Albeit not of true diagnostic value for
the determination of individual infection status, sero-
prevalence surveys using Ov16, especially if conducted
at various time points after the start of CDTI, can pro-
vide important data to understand temporal (and spatial)
trends in exposure patterns. In particular, the serological
testing of children aged ≤10 years could be used as a
tool for evaluating the performance of CDTI pro-
grammes (Table 2).
Serology Testing for Ov16 can be done with an
enzyme-linked immunosorbent assay (ELISA) method or
with the newly developed rapid Ov16 diagnostic test.
The rapid diagnostic test (RDT) has a lower sensitivity
and specificity than the ELISA test, but is cheaper, easier
to perform and provides an immediate result onsite [72].
Ov16 point-of-care serosurveys in children aged up to
10 years have so far been used to decide whether oncho-
cerciasis transmission has been interrupted [43, 45, 46],
but they could also be used for programme evaluation.
The WHO has proposed an Ov16 prevalence of 0.1%
(upper confidence limit) in children below the age of
10 years as a suitable threshold for stopping ivermectin
treatment [34], but in order to reach this threshold large
sample sizes are required and the test specificity should
be 100%. Recent modelling studies have sought to inves-
tigate the optimal age groups to be sampled under vari-
ous scenarios of diagnostic performance using
ONCHOSIM [70], while taking into account that a sin-
gle threshold value may not be appropriate for all levels
of initial endemicity (a similar problem arises with the
pOTTIS not adequately reflecting the true underlying
transmission breakpoints for different baseline endemic-
ities) [26, 28]. Guidelines for using Ov16 serosurveys for
programmatic performance evaluation would also need
to be developed, and mathematical modelling can help
in this endeavour.
As a case study, we performed a survey using the
Ov16 RDT point-of-care test in the Mahenge area in
Tanzania as part of a research project to study the rela-
tionship between the degree of onchocerciasis transmis-
sion and the incidence of epilepsy. A high prevalence of
Ov16 seropositivity (41%; 95% CI = 34–48%) among chil-
dren aged 7–10 years was observed in two villages that
had a high prevalence of epilepsy (> 3%). In these vil-
lages, ivermectin had apparently been distributed for
more than 19 years, and onchocerciasis had been
considered to be well controlled according to reported
treatment coverage data obtained during household sur-
veys (in which about 76% of interviewed individuals
stated having taken ivermectin during the previous year)
Table 2 Advantages and disadvantages of currently available tools for monitoring and evaluation of onchocerciasis control and
elimination programmes
Monitoring tools Advantages Disadvantages
Skin snip surveys during
the treatment implementation
phase
Detection of skin microfilariae is the
gold-standard diagnostic of active
infection. PCR can be used on skin
snips
Need ethical approval*; painful; require
sterilisation of punches between individuals
being sampled; decreasing acceptance by
communities
Ivermectin coverage surveys Relatively easy and affordable;
can provide information about
treatment uptake
May lead to overestimation of coverage
and/or provide incomplete information
about treatment adherence
Ov16 rapid diagnostic test
(RDT) surveys in children
aged up to 10 years
Relatively affordable, immediate
answer on site
Need ethical approval*, sensitivity and
specificity of RDTs not yet well established
Ov16 ELISA surveys in children
aged up to 10 years
Sensitivity of up to 80% and
specificity of up to 97% [72]
Need ethical approval*; more expensive
than RDTs; samples need to be sent to a
lab, often located abroad. Variability in
diagnostic performance according to lab
and presence of other filarial infections [92]
PCR pool screening of
simuliid vectors
No ethical approval needed?*;
many flies can be sampled; in
principle, separate analysis of
flies’ heads and bodies can
provide information on infectivity
to and from human populations
Lack of trained entomologists and labs,
as samples often shipped to reference labs
for PCR analysis; increasing number of flies
needed as infection levels decrease;
sampling protocols need to be refined
*Some ministries of health have given blanket ethical approval for all monitoring and evaluation activities (including skin snips, blood tests and catching flies by
human vector collectors), as part of the control programme activities. Others seem to require approval for specific instances
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(B. Mmbando, unpublished data). However, Tekle et al.
[44] reported that the Mahenge focus had only 7 years
of treatment with > 60% coverage by the time its evalu-
ation by APOC was conducted, with a microfilarial
prevalence of 10 – 45%, in agreement with our sero-
prevalence results.
How such Ov16 serosurveys should be performed in
an ethical way as part of programme evaluation needs to
be established. If, as seems likely, each country needs to
obtain ethical approval for organising Ov16 serosurveys
and if informed consent/assent needs to be obtained
from each individual to be tested, the costs associated
with the testing will be considerable.
Xenomonitoring Molecular xenomonitoring using
blackfly head pools (to detect infection by L3 larvae) has
been proposed by the scientific international community
for evaluation of impact of onchocerciasis elimination
programmes as it provides information on parasite
transmission from vectors to humans. As elimination
programmes progress, testing for blackfly bodies
(abdomens plus thoraces) could provide additional and
useful indicators of transmission from humans to vec-
tors (i.e. uptake of live skin microfilariae that would
otherwise be difficult to detect by skin snips or skin-snip
PCR [73]). It is paramount that molecular xenomonitor-
ing be conducted as part of epidemiological evaluations
as it complements information provided by skin snips or
other techniques [74]. However, the technical expertise
necessary to perform such entomological investigations
in a satisfactory manner (designing well-suited sampling
protocols; determining sample sizes, where to sample;
when to sample; identifying biting simuliids to species,
etc.) is currently lacking in many endemic countries.
Many entomologists with expertise in blackfly vectors
have retired or moved to work in other, better funded
fields, such as malaria. Therefore, there is an urgent need
to train young African entomologists and motivate them
to work on Simuliidae. Catching flies also poses the ethical
problem of how best to do this. The recommended way is
still by human landing capture, which also provides infor-
mation on biting rates. In Ghana, we have tried a number
of strategies, including host-dependent and host-
independent catching methods [73, 75], and others have
tried to develop and optimise (e.g. Esperanza window)
traps that would obviate the need for human attractants
[76, 77]. The advantage of human landing catches is their
comparative value with the standardised methods used by
the OCP [78]. Also they provide the possibility of estimat-
ing biting rates and infective biting rates/transmission
potentials [73, 75] rather than just proportions of flies in-
fected/infective (which devoid of the context of vector
density are non-informative of transmission intensity). As
long as the vector collectors are recruited locally and are
taking regular ivermectin treatment, the procedure is con-
sidered not to be harmful. Ideally, however, as large fly
population samples are needed, and the sample size re-
quired may increase with decreasing infection levels in the
human population, more efficient, non-hazardous, and
large-scale sampling methods will be necessary. Recently,
it has been reported that Esperanza traps may be effectively
operated by community residents and represent a viable
alternative to human landing collections for entomological
surveillance of O. volvulus transmission [79].
Ivermectin efficacy If during regular programme evalu-
ation issues with ivermectin uptake are identified, these
should be picked up by the national elimination commit-
tees, which need to recommend corrective actions.
These may include conducting a coverage verification
study. If coverage is found to be satisfactory, human
(and vector) migration studies may need to be under-
taken. Parasite genetic studies may also need to be consid-
ered if Ov16 serosurveys suggest high levels of ongoing
transmission despite long CDTI duration with good cover-
age. Studies need to investigate potential contributory
factors to decreased ivermectin sensitivity and the impact
that any potential ivermectin resistance may have on
achieving onchocerciasis elimination [80]. Most ivermec-
tin resistance studies had focused on candidate genes (e.g.
beta-tubulin) identified in ivermectin-resistant nematodes
of farmed ruminants (e.g. [81]). Consequently, modelling
work had explored the spread of (recessive) resistance in
one locus-two allele systems (e.g. [82]). However, the
recent work using genome-wide approaches described
earlier has revealed that the phenotype of sub-optimal re-
sponse to ivermectin is likely determined by quantitative
trait loci with many genes contributing in a polygenic
manner [60]. Ongoing modelling studies are focussing on
the impact of the latter upon onchocerciasis elimination
(L.E. Coffeng, pers. comm.).
Treatment, care, and support for persons with
onchocerciasis-associated morbidities should be enhanced
Because of the long-term onchocerciasis control pro-
grammes that have been in place (OCP, APOC, OEPA),
the number of blind and visually impaired people due to
onchocerciasis has decreased substantially as the inci-
dence of infection has decreased (although prevalent
cases of blindness still remain). The burden and psycho-
social consequences of onchocercal skin disease have
been well recognised [83, 84]. There is, however, still
an important morbidity associated with onchocerciasis
that has thus far been largely neglected by most
health care systems, namely onchocerciasis-associated
epilepsy (OAE). Onchocerciasis control programmes
and burden of disease studies have not considered
epilepsy among the sequelae of onchocerciasis (whose
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causal relationship is difficult to ascertain and thus
most studies have been largely ecological [6–8]). This
has resulted in the programmes not addressing this
major public health problem and/or lacking the
means of evaluating its burden and temporal/spatial
evolution. Neurologists are not generally present in
onchocerciasis-endemic regions and mental health ini-
tiatives only tend to consider (neuro) cysticercosis as
the main parasitic disease causing epilepsy. It will be-
come increasingly important that onchocerciasis con-
trol and mental health programmes work together.
Thus both programmes should exchange surveillance
data. Moreover, CDDs could play an important role
in epilepsy surveillance systems, should these be
established, in order to detect persons with new onset
epilepsy early and refer them for treatment promptly.
Even after implementing and strengthening effective
onchocerciasis control programmes, those already af-
fected will continue to suffer even after transmission
has been interrupted.
OAE will potentially make the burden of onchocer-
ciasis disease in Africa considerably greater than pre-
viously thought. Recent studies (in line with previous
reports [85]) suggest that in onchocerciasis endemic
regions, infection by O. volvulus may trigger epilepsy,
with ivermectin effecting some protection against sei-
zures [86–88]. This protection, however, may be only
partial where ivermectin is given on an annual basis
(because adult worms resume production of microfil-
ariae after a few months). Further research needs to
be conducted to ascertain the impact of ivermectin
treatment on the incidence of epilepsy in prospective
studies, but most likely biannual treatment will be ne-
cessary to suppress microfilarial load and potentially
to have a maximal effect on the incidence of OAE.
By eliminating onchocerciasis, it is anticipated that the in-
cidence of OAE will decrease and with it, its burden of
long-term disability. While technically, elimination strat-
egies may not include OAE, it is important to document
it, as it has an impact on compliance at the local level and
is a major but underestimated factor of relevance for ad-
vocating the elimination of onchocerciasis.
Funding should be increased to support operational
research and to help countries with weak onchocerciasis
control to move towards elimination
In addition to ivermectin, the Alternative Treatment
Strategies (ATS) document of APOC (2015) [21] also
outlines the possibility of deploying other strategies
(including focal vector control [71]) and therapies as
they become available for safe use in humans (e.g.
moxidectin; macrofilaricides in the pipeline) or when
they are already available for other indications (e.g.
doxycycline), as well as a number of test-and-treat
options for areas co-endemic with loiasis, sub-optimal
responses to ivermectin, or mop-up settings. In par-
ticular, co-endemicity with loiasis has represented a
major impediment to the expansion and intensifica-
tion of mass ivermectin treatment coverage and com-
pliance for the reasons mentioned above. Inroads into
such challenges have been made possible by recent
technical advances in rapid loiasis diagnostics [89] for
the identification of heavily microfilaraemic individ-
uals at high risk of SAEs who would not be offered
ivermectin. These, however, only represent a small
fraction of the population (1–2%) [90]. This strategy
has proven safe and effective for the implementation
of district-wide, community-based distribution of iver-
mectin in loiasis–onchocerciasis co-endemic areas in
Cameroon [91]. Large-scale implementation trials of
these and other ATS require additional funding to
evaluate not only their feasibility as a proof-of-
concept but crucially their epidemiological impact and
cost-effectiveness.
Countries and areas within countries that currently
have under-performing onchocerciasis control pro-
grammes already suffer from under-staffed and under-
resourced healthcare systems, and allocating scarce
resources to improving onchocerciasis control may
not be at the top of their public health agenda. It is
imperative that OAE is well researched, its association
with O. volvulus infection rigorously established and
recognised, and that future burden of disease studies
include its association with morbidity and mortality.
We hope that recognising OAE as one of the most
important onchocerciasis-associated morbidities and
that assessing its burden on society will motivate
public health decision makers to improve the per-
formance and monitoring of CDTI programmes and
also motivate funders to increase their support for ac-
tions towards the elimination of onchocerciasis.
Conclusions
The long-term aim of programmes against oncho-
cerciasis should remain the interruption of its trans-
mission. It is likely, however, that in several African
countries this goal will not be reached in the 2020–
2025 timeframes proposed by WHO and APOC. In
view of the challenges associated with onchocercia-
sis control, ESPEN’s mandate should be expanded to
include the strengthening of weak onchocerciasis
control programmes. However, one of the major
hurdles for ESPEN will be to reconcile the need for
increased activities around the other four preventive
chemotherapy NTDs under its remit with the spe-
cific requirements of a Pan-African scale elimination
programme. If onchocerciasis is to be eliminated in
Africa, it will be crucial for ESPEN to engage
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promptly and collaboratively with the international
scientific community and major international fun-
ders as well as with other stakeholders to harness
the all-essential technical and financial support that
will be necessary to address this huge endeavour,
identify areas where CDTI programmes are perform-
ing less well than they should, determine the rea-
sons for this, and find novel ways of monitoring,
evaluating and supporting the programmes, as well
as identifying which, where, and when ATS should
be deployed, as they become part of our armoury in
the fight against River Blindness.
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